Surprisingly, another group showed that dual MEK‐PI3K inhibitor therapy somehow significantly reduced KRAS mutated mucin 2 (MUC2) expression, MUC2 palmitoylation, and secretion in colon cells, ultimately suppressing mucinous tumor growth in vivo [127]. The gene discussed is MUC2; the disease is mucinous neoplasm.